About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

EP: 6. Therapeutic Sequencing for ESR1m, ER+, HER2- MBC: Efficacy and Safety Considerations EP: 7. ER+, HER2- MBC: Role of Everolimus in Current Landscape EP: 8. Tissue, ctDNA, and ESR1 Mutation ...

Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ...

Arvinas stock tumbles despite positive trial resultsDespite the positive outcomes for the ESR1m population, the overall survival data is not yet mature, with less than a quarter of the required events ...

Significant improvements to progression-free survival were seen with a hazard ratio of 0.60 in the ESR1m patient subpopulation for patients receiving vepdegestrant monotherapy compared to fulvestrant.

The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival ...

Leerink Partners believes these developments could reshape the standard of care (SoC) and reduce the population of ESR1m patients in the second line who would be eligible for vepdeg treatment. This ...

Leerink Partners' analysis suggests that the success of vepdeg in the ITT population could lead to a broad label for the drug, not limited to ESR1m patients. The firm projects potential unadjusted ...

The primary endpoint was progression-free survival (PFS) in the intent-to-treat and ESR1m populations as determined by blinded independent central review. Overall survival is a key secondary endpoint.

Leerink Partners’ analysis suggests that the success of vepdeg in the ITT population could lead to a broad label for the drug, not limited to ESR1m patients. The firm projects potential unadjusted ...